Inhibikase Therapeutics(NASDAQ) IKT

Inhibikase Therapeutics, Inc. makes medicine for serious lung diseases. Its main product helps patients breathe more easily. The company aims to make therapies safer for patients.

Pills for Better Lung Health

• IKT-001: Oral prodrug designed to treat pulmonary arterial hypertension; a "prodrug" is an inactive compound that becomes medicine only after entering the bloodstream.
• Prodrug Technology: Chemical methods used to modify existing drugs to reduce stomach-related side effects while maintaining clinical efficacy.
• IMPROVE-PAH Trial: Global Phase 3 clinical study evaluating pulmonary vascular resistance and walking distance in patients with lung-related heart disease.

Recent Moves and Milestones

• Acquired CorHepta Pharmaceuticals in February 2025 to expand its pipeline of potential treatments.
• Obtained Orphan Drug Designation from the FDA in July 2026, providing seven years of potential market exclusivity.
• Raised $50.5 million in gross proceeds through an at-the-market stock facility in July 2026.
• Activated 43 clinical sites, or medical testing locations, across 26 countries for its final-stage human study.

How the Science Works

Inhibikase Therapeutics uses chemistry to keep its drugs inactive until they reach the bloodstream. This approach aims to reduce the stomach issues typically caused by similar medications.

Checking the Financial Vitals

• Net loss was $19.6 million for the three months ended June 30, 2026, up 97.6% year over year.
• Research and development expenses reached $13.4 million in the second quarter of 2026, up 154.1% year over year.
• Cash, cash equivalents, and marketable securities totaled $159.0 million as of June 30, 2026.
• Market capitalization was $352.1 million in the second quarter of 2026, up 100.6% year over year.
• Accumulated deficit reached $178.7 million by June 30, 2026, due to recurring losses from research activities.

The Bottom Line

Inhibikase Therapeutics has transitioned into a late-stage clinical company focused on high-need respiratory conditions. Its strategy relies on modifying proven drugs to create safer and more effective treatments for chronic diseases.